FDA Should Deem Atorvastatin Capsule ANDAs Suitable For Submission – Citizen Petition
This article was originally published in The Pink Sheet Daily
Executive Summary
Atorvastatin capsules would be bioequivalent to Pfizer’s Lipitor tablets since the dosage form is the only proposed change to labeling, Lachman Consultant Services says in citizen petition.
You may also be interested in...
Ivax Launches Neurontin Generic As User Fee Date For Pfizer's Pregabalin Nears
Non-AB-rated gabapentin tablets launch "at risk" less than two weeks before the estimated Aug. 30 user fee deadline for Pfizer's follow-on drug Lyrica. Pfizer is seeking a temporary restraining order against Ivax.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states